Three-Dimensional Pharmacology, a Subject Ranging from Ignorance to Overstatements

Pharmacology and Toxicology

Volumn 93, Issue 5, 2003, Pages 203-210

  Waldeck, Bertil ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BUPIVACAINE; CARMOTEROL; CITALOPRAM; DILEVALOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; FORMOTEROL; HALOTHANE; IPRATROPIUM BROMIDE; KETAMINE; LABETALOL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVALBUTEROL; MEPIVACAINE; MONTELUKAST; OFLOXACIN; OMEPRAZOLE; PROMETHAZINE; PROPANOL; SALBUTAMOL; SALMETEROL; SIBENADET; SLOW REACTING SUBSTANCE; THALIDOMIDE; UNINDEXED DRUG; VERAPAMIL; WARFARIN; ZAFIRLUKAST;

BINDING AFFINITY; CARDIOTOXICITY; CHIRALITY; CLINICAL TRIAL; COMPETITIVE INHIBITION; DELIRIUM; DROWSINESS; DRUG BINDING; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENANTIOMER; FETUS MALFORMATION; HUMAN; NONHUMAN; OPTICAL ROTATION; PHARMACODYNAMICS; PHARMACOLOGY; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; STEREOCHEMISTRY; TERATOGENICITY;

PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; STEREOISOMERISM;

EID: 0346874450     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-0773.2003.pto930502.x     Document Type: Short Survey

References (84)

1. Ahrens, R. & M. Weinberger: Levalbuterol and racemic albuterol: Are there therapeutic differences? J. Allergy Clin. Immunol. 2001, 108, 681-684.
2. Andersson, T., M. Hassan-Alin, G. Hasselgren, K. Röhss & L. Weidolf: Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharmacokinet. 2001, 40, 411-426.
3. Ariëns, E. J.: Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol. 1984, 26, 663-668.
4. Ariëns, E. J.: Chirality in bioactive agents and its pitfalls. Trends Pharmacol. Sci. 1986, 7, 200-205.
5. Ariëns, E. J.: Stereoselectivity in the action of drugs. Pharmacology & Toxicology 1989, 64, 319-320.
6. Barlow, R. B., F. M. Franks & J. D. M. Pearson: The relation between biological activity and the degreee of resolution of optical isomers. J. Pharm. Pharmacol. 1972, 24, 753-761.
7. Bernstein, P. R.: The challenge of drug discovery: Developing leukotriene antagonists. In: SRS-A to leukotrienes, The dawning of a new treatment. Ed.: S. Holgate & S.-E. Dahlén. Blackwell Science Ltd., Oxford, UK, 1997, pp. 171-186.
8. Blaschke, G., H. P. Kraft, K. Fickentscher, & F. Köhler: Chromatographische Racemattrennung von Thalidomid und teratogene Wirkung der Enantiomere. Arzneimittelforsch. 1979, 29, 1640-1642.
9. 2-adrenoceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7-(2-aminoethyl)-4-hydroxybenzothiazol-2(3H)-one analogues. J. Med. Chem. 1998, 41, 4915-4917.
10. Boulton, D. W. & J. P. Fawcett: Enantiomselective disposition of salbutamol in man following oral and intravenous administration. Brit. J. Clin. Pharmaocl. 1996, 41, 35-40.
11. Brittain, R. T. & G. P. Levy: A review of the animal pharmacology of labetalol, a combined α-and β-adrenoceptor blocking drug. Brit. J. Clin. Pharmacol. 1976, 3, (Supplement), 681-694.
12. Brittain, R. T., G. M. Drew & G. P. Levy: The α-and β-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Brit. J. Pharmacol. 1982, 77, 105-114.
13. Cahn, R. S., C. K. Ingold & V. Prelog: The specification of asymmetric configuration in organic chemistry. Experientia 1956, 12, 81-94.
14. Cushman, D. W., H. S. Cheung, E. F. Sabo & M. A. Ondetti: Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 1977, 16, 5484-5491.
15. Cushny, A. R.: Biological relations of optically isomeric substances. Baillière, Tindall & Cox, London, 1926.
16. De Camp, W. H.: The FDA perspective on the development of stereoisomers. Chirality 1989, 1, 2-6.
17. Easson, L. H. & E. Stedman: Studies on the relationship between chemical constitution and physiological action. Biochem. J. 1933, 27, 1257-1266.
18. Eichelbaum, M. & A. S. Gross: Stereochemical aspects of drug action and disposition. Adv. Drug Res. 1996, 28, 1-64.
19. Engelhardt, W.: Recovery and psychomimetic reactions following (S)-ketamine. Anaesthesist 1997, 46 Suppl.1, 38-42.
20. Eriksson, T., S. Björkman, B. Roth, Å. Fyge & P. Höglund: Stereospecific determination, chiral interconversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 1995, 7, 44-52.
21. Eriksson, T., S. Björkman, B. Roth & P. Höglund: Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J. Pharm. Pharmacol. 2000, 52, 807-817.
22. Fabro, S., R. L. Smith & R. T. Williams: Toxicity and teratogenicity of optical isomers of thalidomide. Nature 1967, 215, 296.
23. Green, S. A., A. P. Spasoff, R. A. Coleman, M. Johnson & S. B. Liggett: Sustained activation of a G protein-coupled receptor via "anchored" agoist binding. J. Biol. Chem. 1996, 271, 24029-24035.
24. Handley, D. A., J. R. McCullough, S. D. Cowther & J. Morley: Sympathomimetic enantiomers and asthma. Chirality 1998a, 10, 262-272.
25. Handley, D. A., J. Morley & L. Vaickus: Levalbuterol hydrochloride. Exp. Opin. Invest. Drugs 1998b, 7, 2027-2041.
26. Handley, D. A., C. H. Senanayake, W. Dutczak, J. L. Benovic, T. Walle, R. B. Penn, H. S. Wilkinson, G. J. Tanoury, R. G. G. Andersson, F. Johansson & J. Morley: Biological actions of formoterol isomers. Pulm. Pharmacol. Ther. 2002, 15, 135-145.
27. Hirota, K., T. Sato, S. F. Rabito, E. K. Zsigmond & A. Matsuki: Relaxant effect of ketamine and its isomers on histamine-induced contractions of tracheal smooth muscle. Brit. J. Anaesth. 1996, 76, 266-270.
28. Hitzl, M., K. Klein, U. M. Zanger, P. Fritz, A. K. Nüssler, P. Neuhaus & M. F. Fromm: Influence of omeprazole on multidrug resistance protein 3 expression in human liver. J. Pharmacol. Exp. Therap. 2003, 304, 524-530.
29. Honda, K., T. Takenaka, A. Miyata-Osawa & M. Terai: Adrenoceptor blocking properties of the stereoisomers of amosulalol (YM-09538) and the corresponding desoxyderivative (YM-11133). J. Pharmacol. Exp. Theraå. 1986, 236, 776-783.
30. Ihmsen, H., G. Geisslinger & J. Schüttler: Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. Clin. Pharmacol. Therap. 2001, 70, 431-438.
31. Jackson, E. K.: Renin and angiotensin. In: Goodman & Gilman's The Pharmacological Basis of therapeutics, 10th edn. Eds.: J. G. Hardman, L. E. Limbird & A. Goodman Gilman. McGraw-Hill, New York, USA, 2001, pp.809-841.
32. Jamali, F., R. Mehvar & F. M. Pasutto: Enantioselective aspects of drug action and disposition: Therapeutic Pitfalls. J. Pharmaceut. Sci. 1989, 78, 695-715.
33. Johnson, M.: Salmeterol. Med. Res. Rev. 1995, 15, 225-257.
34. Jones, T. R., M. Labelle, M. Belley, E. Champion, L. Charette, J. Evans, A. W. Ford-Hutchinson, J. Y. Gauthier, A. Lord, P. Masson, M. McAuliffe, C. S. McFarlane, K. M. Metters, C. Pickett, H. Piechuta, C. Rochette, I. W. Rodger, N. Sawyer, R. N. Young, R. Zamboni & W. M. Abraham: Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol. 1995, 73, 191-201.
35. 3-adrenoceptor-deficient brown adipocytes. Amer. J. Physiol. Endocrinol. Metabol. 2002, 283, E146-E153.
36. Kenakin, T. P.: An in vitro quantitative analysis of the alpha adrenoceptor partial agonist activity of dobutamine and its relevance to inotropic selectivity. J. Pharmacol. Exp. Therap. 1981, 216, 210-219.
37. 2-selectivity of TA-2005, a newly developed bronchodilating agent, in guinea-pig tissues. Jap. J. Pharmacol. 1991, 57, 175-185.
38. Klepstad, P., A. Maurset, E. R. Moberg & I. Øye: Evidence of a role for NMDA receptors in pain perception. Eur. J. Pharmacol. 1990, 187, 513-518.
39. Knoche, B. & G. Blaschke: Investigations on the in vitro racemization of thalidomide by HPLC. J. Chromatogr. 1994, A666, 235-240.
40. Krell, R. D., D. Aharony, C. K. Buckner, R. A. Keith, E. J. Kusner, D. W. Snyder, P. R. Bernstein, V. G. Matassa, Y. K. Yee, F. J. Brown, B. Hesp & R. G. Giles: The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist. Amer. J. Resp. Dis. 1990, 141, 978-987.
41. Lehmann, P. A.: Stereoisomerism and drug action. Trends Pharmacol. Sci. 1986, 7, 281-285.
42. Lindberg, P., D. Keeling, J. Fryklund, T. Andersson, P. Lundborg & E. Carlsson: Review article: esomeprazole - bio-availability, specificity for the proton pump and inhibition of acid secretion. Aliment. Pharmacol. Therap. 2003, 17, 481-488.
43. Lötvall, J., M. Palmqvist, P. Arvidsson, A. Maloney, G. P. Ventressa & J. Ward: The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J. Allergy Clin. Immunol. 2001, 108, 726-731.
44. Mason, S.: The origin of chirality in nature. Trends Pharmacol. Sci. 1986, 7, 20-23.
45. 2-selective sympathomimetics. Pulm. Pharmacol. 1994, 7, 367-376.
46. McClellan, K. J. & D. Faulds: Ropivacaine: An update of its use in regional anaesthsia. Drugs 2000, 60, 1065-1093.
47. Montpetit, C. J. & S. F. Perry: Adrenergic regulation of catecholamine secretion from trout (Oncorhynchus mykiss) chromaffin cells. J. Endocrinol. 2002, 173, 187-197.
48. Murase, K., T. Mase, H. Ida, K. Takahashi & M. Murakami: Absolute configuration of four isomers of 3-formamido-4-hydroxy-α-[[N-(p-methoxy- α-methylphenethyl)amino]methyl]benzylalcohol, a potent β-adrenoceptor stimulant. Chem. Pharm. Bull. 1978, 26, 1123-1129.
49. Nelson, H. S., G. Bensch, W. W. Pleskow, R. DiSantostefano, S. DeGraw, D. S. Reasner, T. E. Rollins & P. D. Rubin: Improved bronchodilation with levoalbuterol compared with racemic albuterol in patients with asthma. J. Allergy Clin. Immunol. 1998, 102, 943-952.
50. Pabelick, C. M., K. Rehder, K. A. Jones, R. Shumway, S. G. E. Lindahl & D. O. Warner: Stereospecific effects of ketamine enantiomers on canine tracheal smooth muscle. Brit. J. Pharmacol. 1997, 121, 1378-1382.
51. Patil, P. N.: A use of the isomeric ratio as a criterion to differentiate adrenergic receptors. J. Pharm. Pharmacol. 1969, 21, 628-629.
52. Patil, P. N., D. D. Miller & U. Trendelenburg: Molecular geometry and adrenergic drug activity. Pharmacol. Rev. 1975, 26, 323-392.
53. Pauwels, R. A., C.-G. Löfdahl, D. S. Postma, A. E. Tattersfield, P. O'Byrne, P. J. Barnes & A. Ullman: Effect of inhaled formoterol and budesonide on exacerbationsof asthma. New Engl. J. Med. 1997, 337, 1405-1411.
54. Persson, J., J. Hasselström, A. Maurset, I. Øye, J.-O. Svensson, O. Almqvist, H. Scheinin, L. L. Gustafsson & O. Almqvist: Pharmacokinetic and non-analgesic effects of S-and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. Eur. J. Clin. Pharmacol. 2002, 57, 869-875.
55. Pfeiffer, C. C.: Optical isomerism and pharmacological action, a generalisation. Science 1956, 124, 29-31.
56. 1-adrenergic stimulation. Can. J. Physiol. Pharmacol. 2002, 80, 569-577.
57. 2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002, 360, 1293-1299.
58. Ruffolo, R. R., Jr. & K. Messick: Inotropic selectivity of dobutamine enantiomeres in the pithed rat. J. Pharmacol. Exp. Therap. 1985, 235, 344-348.
59. Ruffolo, R. R., Jr. & E. L. Yaden: Vascular effects of the stereoisomers of dobutamine. J. Pharmacol. Exp. Therap. 1983, 224, 46-50.
60. Ruffolo, R. R., Jr., T. A. Spradlin, G. D. Pollock, J. E. Waddell & P. J. Murphy: Alpha and beta adrenergic effects of the stereoisomers of dobutamine. J. Pharmacol. Exp. Therap. 1981, 219, 447-452.
61. Ruffolo, R. R., Jr., K. Messick & J. S. Horng: Interactions of the enantiomers of 3-O-methyldobutamine with α-and β-adrenoceptors in vitro. Naunyn-Schmiedeberg's Arch. Pharmacol. 1985, 329, 244-252.
62. Sampaio, E. P., E. N. Sarno, R. Galilly, Z. A. Cohn & G. Kaplan: Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J. Exp. Med. 1991, 173, 699-703.
63. Samuelsson, B.: The discovery of the leukotrienes and the structure elucidation of SRS-A. In: SRS-A to leukotrienes, The dawning of a new treatment. Eds.: S. Holgate & S.-E. Dahlén. Blackwell Science Ltd., Oxford, UK, 1997, pp. 39-49.
64. Sanjar, S. & J. Morley: Airway hyperreactivity. Lancet 1988, 2, 160-161.
65. Schmidt, D., B.-L. Källström, B. Waldeck, D. Branscheid, H. Magnusson & K. F. Rabe: The effect of the enantiomers of formoterol on inherent and induced tone in guinea-pig trachea and human bronchus. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 361, 405-409.
66. Sheskin, J.: Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Therap. 1965, 6, 303-306.
67. Smith, D. F.: The stereoselectivity of drug action. Pharmacology & Toxicology 1989, 65, 321-331.
68. Testa, B., P.-A. Carrupt & J. Gal: The so-called " interconversion" of stereoisomeric drugs: An attempt at clarification. Chirality 1993, 5, 105-111.
69. Trofast, J., K. Österberg, B.-L. Källström & B. Waldeck: Steric aspects of agonism and antagonism at β-adrenoceptors: Synthesis of and pharmacological experiments with the enantiomers of formoterol and their diastereomers. Chirality 1991, 3, 443-450.
70. Tucker, G. T.: Chiral switches. Lancet 2000, 355, 1085-1087.
71. Tuttle, R. R. & J. Mills: Development of a new catecholamine to selectively increase cardiac contractility. Circ. Res. 1975, 36, 185-196.
72. Vidal-Beretervide, K.: Effects of (±) dobutamine and its (+) and (-) enantiomers in the isolated rat portal vein. Fundam. Clin. Pharmacol. 1991, 5, 237-244.
73. 2-adrenoceptor agonists in asthma: molecular pharmacological aspects. Thesis, Vrije Universiteit, Amsterdam, 1994.
74. 2-adrenoceptor agonist, TA-2005. Eur. J. Pharmacol. 1992, 227, 403-409.
75. Waldeck, B.: Biological significance of the enantiomeric purity of drugs. Chirality 1993, 5, 350-355.
76. 2- adrenoceptor agonists: Is there a cause for concern? J. Allergy Clin. Immunol. 1999, 103, 742-748.
77. Waldeck, B.: β-Adrenoceptor agonists and asthma - 100 years of development. Eur. J. Pharmacol. 2002, 445, 1-12.
78. Walle, U. K., G. R. Pesola & T. Walle: Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity. Brit. J. Clin. Pharmacol. 1993, 35, 413-418.
79. Wallin, J. D. & W. H. Frishman: Dilevalol: a selective beta-2 adrenergic agonist vasodilator with beta adrenergic blocking activity. J. Clin. Pharmacol. 1989, 29, 1057-1068.
80. Weiner, N.: Drugs that inhibit adrenergic nerves and block adrenergic receptors. In: Goodman & Gilman's The pharmacological Basis of Therapeutics, 6th edn. Eds.: A. Goodman Gilman, L. S. Goodman & A. Gilman. MacMillan Publishing Co, New York, USA, 1980, pp.176-210.
81. White, P. F., W. I. Way & A. J. Trevor: Ketamine - its pharmacology and therapeutic uses. Anesthesiology 1982, 56, 119-136.
82. Wnendt, S., M. Finkam, W. Winter J. Ossig, G. Raabe & K. Zwingenberger: Enantioselective inhibition of TNF-α release by thalidomide and thalidomide analogues. Chirality 1996, 8, 390-396.
83. Zeilhofer, H. U., D. Swandulla, G. Geisslinger & K. Brune: Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur. J. Pharmacol. 1992, 213, 155-158.
84. Äbelö, A., T. Andersson, M. Antonsson, A. Naudot, I. Skånberg & L. Weidolf: Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab. Dispos. 2000, 28, 966-972.